Introduction for tirzepatide injection for type 2 diabetes (Mounjaro）and for weight loss(Zepbound)

Eli Lilly's once-weekly dual GIP and GLP-1 receptor agonist Mounjaro injection is used as an adjunctive therapy to diet and exercise to improve blood sugar control in adults with type 2 diabetes. Zepbound injection is used for weight loss. Weight Losing

Effect: 26.6% for 84 weeks treatment Tirzepatide can significantly reduce the glycated hemoglobin (HbA1c) by 2.0%

 

Strength: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg per vial Storage Condition: Protect from light, sealed, 2-8°C preservation

 

API and Injection Production

API production scale and capacity: GMP grade facility.

Injection: GMP grade facility

Lyo powder: GMP grade facility